MyFinsight
Home
Blog
About
Cash and cash
equivalents
$45,089,786
(9.33%↑ Y/Y)
Prepaid expenses and
other current assets
$2,289,120
(-13.24%↓ Y/Y)
Total current assets
$47,378,906
(-43.97%↓ Y/Y)
Right-of-use assets
$141,109
(-65.13%↓ Y/Y)
Fixed assets, net
$20,544
Total assets
$47,540,559
(-44.05%↓ Y/Y)
Total liabilities and
stockholders equity
$47,540,559
(-44.05%↓ Y/Y)
Total stockholders
equity
$37,885,303
(-31.48%↓ Y/Y)
Total liabilities
$9,655,256
(-67.46%↓ Y/Y)
Accumulated deficit
-$492,860,145
(-4.91%↓ Y/Y)
Additional paid-in capital
$530,685,127
(1.07%↑ Y/Y)
Total current
liabilities
$9,655,256
(-67.31%↓ Y/Y)
Common stock, voting,
0.001 par value...
$60,321
(0.46%↑ Y/Y)
Deferred collaboration
revenue
$6,000,000
(0.00%↑ Y/Y)
Accrued expenses
$3,374,333
(-49.36%↓ Y/Y)
Operating lease
liabilities
$143,447
(-45.57%↓ Y/Y)
Accounts payable
$137,476
(-90.55%↓ Y/Y)
Back
Back
Balance Sheet
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)
source: myfinsight.com